Gentile Gaétan, Jego Maeva, Spadari Michel, Griffiths Karolina, Jouanjus Emilie, Micallef Joëlle
Département Universitaire de Médecine Générale, Faculté de Médecine, Aix Marseille Université, 27 boulevard Jean Moulin, Marseille, 13385, France.
Institut des Neurosciences des Systèmes, INSERM 1106, Aix Marseille Université, INSERM, INS, Inst Neurosci Syst, Faculté Médecine Timone, 27 Bd Jean Moulin, 133855, Marseille, France.
Fundam Clin Pharmacol. 2018 Dec;32(6):643-651. doi: 10.1111/fcp.12401. Epub 2018 Aug 5.
Addictovigilance is a health vigilance dedicated to the survey of medicinal or illicit psychoactive substance use disorders (SUDs). France is the only European country to have a vigilance system specifically dedicated to substances with an abuse/addiction potential. The French Addictovigilance system is organized in a network of regional tertiary centres (called Abuse and Dependence Monitoring Centres, CEIP-Addictovigilance) and works in close collaboration with Regional and National health authorities. Because of the essential and unavoidable nature of their practice in the French Healthcare system, general practitioners (GPs) are key actors to identify and track Addictovigilance signals. They have been involved in several of the pharmacoepidemiological surveys implemented by the French Addictovigilance Network (FAN). Now, they increasingly participate in clinical research projects and studies. In this article, interactions between GPs and the FAN are illustrated with two examples: patients on opioid substitution treatment and patients on opioid analgesics. Collaborations between GPs and the FAN could be further potentiated. In particular, more effective communication on psychoactive SUDs including abuse/addiction is necessary to optimize the implementation of preventive measures for patients on psychoactive substances medications, and to improve the attitudes of GPs and more widely health professionals in the management of any psychoactive user suffering from SUDs. In addition, both adapted training and improved collaborative research could contribute to the optimization (safety, quality) of professional practices.
药物警戒是一项致力于调查药用或非法精神活性物质使用障碍(SUDs)的健康警戒工作。法国是欧洲唯一拥有专门针对具有滥用/成瘾潜力物质的警戒系统的国家。法国药物警戒系统由区域三级中心网络(称为滥用与依赖监测中心,CEIP - 药物警戒)组成,并与区域和国家卫生当局密切合作。由于全科医生(GPs)在法国医疗保健系统中的实践具有必要性和不可避免性,他们是识别和追踪药物警戒信号的关键角色。他们参与了法国药物警戒网络(FAN)实施的多项药物流行病学调查。现在,他们越来越多地参与临床研究项目和研究。在本文中,通过两个例子说明了全科医生与FAN之间的互动:接受阿片类药物替代治疗的患者和使用阿片类镇痛药的患者。全科医生与FAN之间的合作可以进一步加强。特别是,有必要就包括滥用/成瘾在内的精神活性物质使用障碍进行更有效的沟通,以优化对使用精神活性物质药物患者的预防措施的实施,并改善全科医生以及更广泛的卫生专业人员对任何患有物质使用障碍的精神活性物质使用者的管理态度。此外,适当的培训和改进的合作研究都有助于优化专业实践(安全性、质量)。